Tairx, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 12, 2019 at 10:00 am EDT
Share
TaiRx, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced operating loss was TWD 43.370 million compared to TWD 52.743 million a year ago. Net loss was TWD 40.758 million compared to TWD 50.519 million a year ago. Basic loss per share was TWD 0.6 compared to TWD 0.75 a year ago. For the half year, operating loss was TWD 85.397 million compared to TWD 88.514 million a year ago. Net loss was TWD 81.739 million compared to TWD 85.916 million a year ago. Basic loss per share was TWD 1.2 compared to TWD 1.28 a year ago.
TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.
TAIRX, INC. 
